The abstract is read at the publisher; the summary is JClub's.
In the Swedish Biopark cohort, PRM-verified plasma peptides from C9 and APOC3 show altered levels in Parkinson’s disease, and SAA1 is linked to cognitive and motor impairment.
- Why it matters: Fluid biomarkers for Parkinson’s disease are limited, and non-motor cognitive decline is especially debilitating, creating a need for plasma markers that reflect disease processes.
- What they did: Plasma from 198 individuals (130 PD, 68 controls) was TMT-tagged, pre-fractionated, and profiled by untargeted mass spectrometry, with PRM technical verification and comparisons to SIMOA-measured Neurofilament light chain.
- The result: After PRM verification, C9 and APOC3 peptides differed between PD and controls, and SAA1 was associated with both cognitive and motor impairment; Neurofilament light chain was elevated with cognitive impairment but correlated more weakly.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.